Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-10-03
2006-10-03
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S299000, C546S112000, C546S124000
Reexamination Certificate
active
07115628
ABSTRACT:
Certain novel bridged piperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.
REFERENCES:
patent: 5281585 (1994-01-01), Duggan et al.
patent: 5576290 (1996-11-01), Hadley
patent: 5721251 (1998-02-01), Chen et al.
patent: 6051555 (2000-04-01), Hadley
patent: 6166037 (2000-12-01), Budhu et al.
patent: 6350760 (2002-02-01), Bakshi et al.
patent: 6458790 (2002-10-01), Palucki et al.
patent: 2002/0091115 (2002-07-01), Dyatkin et al.
patent: 0 512 831 (1992-11-01), None
patent: 0 512 831 (1999-09-01), None
patent: 1115817 (1968-05-01), None
patent: WO 99/09984 (1999-03-01), None
patent: WO 99/64002 (1999-12-01), None
patent: WO 00/53148 (2000-09-01), None
patent: WO 00/74649 (2000-12-01), None
patent: WO 00/74679 (2000-12-01), None
patent: WO 01/58891 (2001-08-01), None
patent: WO 01/70337 (2001-09-01), None
patent: WO 01/70708 (2001-09-01), None
patent: WO 01/91752 (2001-12-01), None
patent: WO 02/067869 (2002-09-01), None
patent: WO 02/068387 (2002-09-01), None
patent: WO 02/068388 (2002-09-01), None
patent: WO 03/009847 (2003-02-01), None
Hall et al. “Obesity hypertension . . . ” CA 136:67681 (2001).
Mountjoy “Cloning of the melanocortin receptors” CA 134:703799 (2000).
Villani et al. “Derivatives of 2-azabicyclo[2,2,2]octane . . . ” J. Med. Chem. v.12, 933-4 (1969).
Huszar et al., Cell, vol. 88 (1997), pp. 131-141, “Targeted disruption of the melanocortin-4 receptor results in obesity in mice”.
Dinsmore et al., Brit. Med. J., vol. 318 (1999), pp. 387-390, “ABC of sexual health—erectile dysfunction”.
Kask et al., Biochem. & Biophys. Res. Comm., vol. 245 (1998), pp. 90-93, “Selective antagonist for the melanocortin 4 receptor (HSO014) increases food intake in free-feeding rats”.
Chen et al., Cell, vol. 91 (1997), pp. 789-798, “Exocrine gland dysfunction in MC5-R-deficient mice . . . ”.
Gingell et al., Exp. Opin. Ther. Patents, vol. 9 (1999), pp. 1689-1696, “Emerging pharmacological therapies for erectile dysfunction”.
Moreland et al., Life Sciences, vol. 62, No. 20 (1998), pp. PL-309-318, “Sildenafil, A novel inhibitor of phosphodiesterase Type 5 in human corpus cavernosum smooth muscle cells”.
Giraudo et al., Brain Res. vol. 809 (1998), pp. 302-306, “Feeding effects of hypothalamic injection of melanocortin 4 receptor ligands”.
Graul, Drugs News & Perspectives, vol. 9 (1996), pp. 572-575, “Latest findings on the diagnosis and treatment of erectile dysfunction”.
Street et al., J. Med. Chem., vol. 33 (1990), pp. 2690-2697, “Synthesis and biological activity of 1,2,4-oxadiazole derivatives . . . ”.
Yang et al., Molec. Endocrinology, vol. 11 (1997), pp. 274-280, “Effects of recombinant agouti-signaling protein on melanocortin action”.
McKenna et al., Pharmacol. Biochem. & Behavior, vol. 40 (1991), pp. 151-156, “Modulation by peripheral serotonin of the threshold for sexual reflexes in female rats”.
Takahashi et al., Brain Res., vol. 359 (1985), pp. 194-207, “Dual estradiol action in diencephalon and the regulation of sociosexual behavior in female golden hamsters”.
Olofson et al., J. Org. Chem., vol. 49 (1984), pp. 2081-2082, “A new reagent for the selective, high-yield N-dealkylation of tertiary amines . . . ”.
Yoram et al., Current Opinion in Urology, vol. 7 (1997), pp. 349-353, “Oral pharmacotherapy in erectile dysfunction”.
Heaton et al., Int'l J. of Importenc Res., vol. 9 (1997), pp. 115-121, “A therapeutic taxonomy of treatments for erectile dysfunction: an evolutionary imperative”.
Dorr et al., Life Sciences, vol. 58, No. 20 (1996), pp. 1777-1784, “Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study”.
Wessells et al., Urology, vol. 56 (2000), pp. 641-646, “Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction”.
Campbell et al., Tetrahedron, vol. 48 (1992), pp. 8751-8774, “Synthesis of 5-homoshikimic acid and some fluorinated derivatives as potential inhibitors of 5-enolpyruvylshikimate-3-phosphate synthase”.
McKenna et al., Am. J. Physiol. 261 (Regulatory Integrative Comp. Physiol. 30): R1276-R1285 (1991), “A model for the study of sexual function in anesthetized male and female rats”.
Imai et al., Database STN No. 108:150205, Chem. Phar. Bull, vol. 35, No. 7 (1987), pp. 2646-2655, “Highly regioselective synthesis of trisubstituted pyrrolidines by 1,3-cycloaddition”.
Getting et al., Chem. Abstracts., vol. 133:159566a (2000), “MC3-R as a novel target for antiinflammatory therapy”.
Budhu et al., Chem. Abstracts., vol. 130:223167p (1999), “Preparation of piperidinylpyrrolidins as modulators of chemokine receptor activity”.
Wessels et al., J. of Urology, vol. 160 (1998), pp. 389-393, “Synthetic melanotropic peptide initiates errections in men with psyhcogenic erectile dysfunction . . . ”.
Uckert et al., Exp. Opin. Invest. Drugs, vol. 12 (2003), pp. 1521-1533, “Current and future trneds in the oral pharmacotherapy of male erectile dysfunction”.
Chaki et al., Exp. Opinion on Therap. Patents, vol. 11 (2001), pp. 1677-1692, “Recent advances in feeding suppressing agents: potential therapeutic strategy for the treatment of obesity”.
Corcos et al., Society for Neuroscience Abstracts, vol. 23 (1997), Abstract No. 267.9, p. 673, “HP 228 is a potent agonist of melanocortin receptor 4, and significantly attenuates obesity and diabetes in Zucker fatty rats”.
Peptides: Frontiers of Peptide Science, Proceedings of the 15th American Peptide Symposium, Jun. 14-19, 1997, Nashville, TN.
Tomlinson et al., Database STN No. 135:166844 (2001), “Preparation of piperazinyl and piperidinyl ketones useful for treating or preventing neuronal damage and for stimulating nerve growth”.
Barakat Khaled J.
Guo Liangqin
Nargund Ravi P.
Sebhat Iyassu K.
Ye Zhixiong
Brown Baerbel R.
Chang Celia
Merck & Co. , Inc.
Winokur Melvin
LandOfFree
Bridged piperidine derivatives as melanocortin receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bridged piperidine derivatives as melanocortin receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bridged piperidine derivatives as melanocortin receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3718045